DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Brown JP, Roux C, Törring O. et al.
Discontinuation of denosumab and associated fracture incidence: Analysis from
the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months
(FREEDOM) Trial.
J Bone Miner Res 2013;
28: 746-752
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.